Phyllodes Tumors

Introduction & Epidemiology - Leafy Tumors Unveiled

• Rare fibroepithelial neoplasms, <1% of all breast tumors.
• Named for "leaf-like" (Greek: phyllon) architecture due to intracanalicular growth pattern with stromal fronds.
• Typically affect women aged 40-50 years (older than fibroadenoma peak).
• Crucial to differentiate from fibroadenoma; Phyllodes show ↑ stromal cellularity & atypia.

  ⭐ Unlike fibroadenomas (usually benign), Phyllodes tumors exist on a spectrum: benign (~60-75%), borderline (~15-20%), malignant (~10-20%).

Pathology & Classification - The Good, Bad, Ugly

• Biphasic: epithelial & stromal. Stromal component dictates behavior.
• Grading criteria: stromal cellularity, atypia, mitoses, overgrowth, margins.
• WHO Classification: Benign, Borderline, Malignant.

⭐ Malignant Phyllodes tumors can metastasize, most commonly to the lungs; lymph node metastasis is rare (< 1%).

Clinical Presentation & Diagnosis - Spotting the Phyllodes

• Age: Typically 40-50 yrs (10-20 yrs older than fibroadenoma peak).
• Mass: Rapidly enlarging, often large (>3-5 cm), firm, mobile, painless. "Leaf-like" (phyllon) lobulations. 📌 Phyllodes: "Fills" the breast (large, rapid growth).
• Skin: Stretched, shiny, engorged veins. Ulceration/fungation in large/malignant cases. Axillary nodes usually negative (hematogenous spread for malignant).

• Imaging:
  • USG: Well-circumscribed, lobulated mass, heterogeneous echotexture, often with cystic clefts/spaces. No pathognomonic features.
  • Mammography: Large, rounded, or lobulated dense mass with well-defined margins. Calcifications uncommon.
• Biopsy:

> ⭐ Core Needle Biopsy (CNB) is crucial; FNAC is unreliable for Phyllodes diagnosis and grading, often misdiagnosing it as fibroadenoma.

Management - Excising the Enigma

• Goal: Complete surgical removal with clear margins.
• Wide Local Excision (WLE): Standard. Aim for ≥1 cm negative margins.
  • Key to prevent local recurrence.
• Mastectomy: For large/recurrent tumors, or malignant phyllodes if WLE unfeasible/margins positive.
• Axillary Surgery: Generally NOT indicated (hematogenous spread).
• Adjuvant Therapy:
  • Radiotherapy (RT): Consider for borderline/malignant, large tumors, or close margins post-WLE to ↓ recurrence.
  • Chemotherapy: Limited role; for metastatic or selected high-grade malignant cases.
  • Hormonal therapy: Ineffective.

⭐ Achieving negative surgical margins, ideally ≥1 cm, is the single most important factor in preventing local recurrence of phyllodes tumors.

Prognosis & Follow-up - Watching for Return

• Local recurrence: Main concern; risk ↑ with positive margins & higher grade.
  • Benign: ~10-17%; Borderline: ~14-25%; Malignant: ~20-30%.
  • Recurrences can show increased grade.
• Metastasis: Primarily with malignant tumors (~10-20%); hematogenous.

  ⭐ Malignant phyllodes: hematogenous spread, commonly to lungs.

• Follow-up: Regular clinical exams & imaging (mammogram/USG).
  • Malignant: More frequent surveillance; consider chest imaging for metastases.

High‑Yield Points - ⚡ Biggest Takeaways

• Phyllodes tumors: fibroepithelial neoplasms with leaf-like projections, distinct from fibroadenomas.
• Graded benign, borderline, or malignant based on stromal features (cellularity, atypia, mitoses).
• Typically a large, rapidly growing, painless mass in women aged 40-50 years.
• Malignant phyllodes spread hematogenously (mainly lungs); nodal metastasis is rare.
• Treatment: wide local excision with ≥1 cm clear margins. Mastectomy for large/recurrent tumors.
• Axillary dissection is generally not indicated.
• Adjuvant therapy for selected malignant or recurrent cases_